Literature DB >> 3036204

Ascorbate depletion as a consequence of product recycling during dopamine beta-monooxygenase catalyzed selenoxidation.

S W May, H H Herman, S F Roberts, M C Ciccarello.   

Abstract

The competence of dopamine beta-monooxygenase (DBM) to process selenide substrates was investigated, in anticipation that the expected selenoxide products would exhibit unique reactivity and redox properties. The prototypical selenide phenyl 2-aminoethyl selenide (PAESe) was synthesized and shown to be a substrate for DBM with the characteristic e/O2 ratio of 2:1 for monooxygenation. The kinetic parameters for oxygenation of PAESe were found to be similar to those for the DBM-catalyzed sulfoxidation of the cognate sulfide phenyl 2-aminoethyl sulfide [May, S. W., & Phillips, R. S. (1980) J. Am. Chem. Soc. 102, 5981-5983], and selenoxidation was stimulated by fumarate in a manner similar to other well-characterized DBM monooxygenation reactions. Identification of phenyl 2-aminoethyl selenoxide (PAESeO) as the enzymatic product was accomplished by the demonstration of coincident elution of authentic PAESeO with the enzymatic product in three significantly different HPLC systems. PAESeO was found to oxidize ascorbic acid with the concomitant and stoichiometric reduction of PAESeO back to the selenide, PAESe. As a consequence of this nonenzymatic reaction, ascorbate-supported DBM turnover was prematurely terminated under standard assay conditions due to depletion of reduced ascorbate. The kinetics of the redox reaction between PAESeO and ascorbate were investigated with a spectrophotometric assay of ascorbate at 300 nm, and a second-order rate constant of 3.4 M-1 s-1 was determined at pH 5.0, 25 degrees C. Spectrophotometric assay of cytochrome c (cyt c) reduction at 550 nm during the oxidation of ascorbate by PAESeO demonstrated that no cyt c trappable semidehydroascorbate was produced in this nonenzymatic reaction.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3036204     DOI: 10.1021/bi00380a021

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Pharmacokinetics, antitumor and cardioprotective effects of liposome-encapsulated phenylaminoethyl selenide in human prostate cancer rodent models.

Authors:  Jeong Yeon Kang; Mathew Eggert; Shravanthi Mouli; Ibrahim Aljuffali; Xiaoyu Fu; Ben Nie; Amy Sheil; Kendall Waddey; Charlie D Oldham; Sheldon W May; Rajesh Amin; Robert D Arnold
Journal:  Pharm Res       Date:  2014-08-27       Impact factor: 4.200

Review 2.  Copper active sites in biology.

Authors:  Edward I Solomon; David E Heppner; Esther M Johnston; Jake W Ginsbach; Jordi Cirera; Munzarin Qayyum; Matthew T Kieber-Emmons; Christian H Kjaergaard; Ryan G Hadt; Li Tian
Journal:  Chem Rev       Date:  2014-03-03       Impact factor: 60.622

Review 3.  Selenium-based antihypertensives. Rationale and potential.

Authors:  S W May; S H Pollock
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

4.  Reduction of L-methionine selenoxide to seleno-L-methionine by endogenous thiols, ascorbic acid, or methimazole.

Authors:  Renee J Krause; Adnan A Elfarra
Journal:  Biochem Pharmacol       Date:  2008-09-27       Impact factor: 5.858

5.  Interaction of non-conjugated olefinic substrate analogues with dopamine beta-monooxygenase: catalysis and mechanism-based inhibition.

Authors:  S R Sirimanne; S W May
Journal:  Biochem J       Date:  1995-02-15       Impact factor: 3.857

6.  The Cardioprotective Mechanism of Phenylaminoethyl Selenides (PAESe) Against Doxorubicin-Induced Cardiotoxicity Involves Frataxin.

Authors:  Xiaoyu Fu; Mathew Eggert; Sieun Yoo; Nikhil Patel; Juming Zhong; Ian Steinke; Manoj Govindarajulu; Emine Akyuz Turumtay; Shravanthi Mouli; Peter Panizzi; Ronald Beyers; Thomas Denney; Robert Arnold; Rajesh H Amin
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.